Apimeds Pharmaceuticals US, Inc. (APUS) Stock

NYSE MKT: APUSHealthcare company in the specialty & generic drug manufacturers industry, based in Matawan, NJ.

Apimeds Pharmaceuticals US stock price chart

APUS interactive chart →

APUS stock quote & key statistics

Apimeds Pharmaceuticals US earnings per share

Income →
Earnings per share

Apimeds Pharmaceuticals US revenue & net income

Income →
RevenueNet income

Apimeds Pharmaceuticals US annual financials

Income statement →
Fiscal yearRevenueNet incomeEPS
FY2025$0-$6.0M-$1.37
FY2024$0-$1.4M—
FY2023$0-$777,694—
FY2022$0-$668,666—
FY2021$0-$1.0M—

Fiscal year ending December 31. Source: company filings via EODHD.

About Apimeds Pharmaceuticals US, Inc.

Apimeds Pharmaceuticals US, Inc. provides digital asset treasury solutions in bitcoin treasury infrastructure. The company was incorporated in 2020 and is based in Matawan, New Jersey. Apimeds Pharmaceuticals US, Inc. operates as a subsidiary of Inscobee., Inc.

Apimeds Pharmaceuticals US stock FAQ

What is the Apimeds Pharmaceuticals US stock ticker symbol?

Apimeds Pharmaceuticals US, Inc. trades on the NYSE MKT under the ticker symbol APUS.

What sector and industry is Apimeds Pharmaceuticals US in?

Apimeds Pharmaceuticals US, Inc. is classified in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry.

How many employees does Apimeds Pharmaceuticals US have?

Apimeds Pharmaceuticals US, Inc. has about 2 full-time employees.

What were Apimeds Pharmaceuticals US's revenue and earnings last fiscal year?

Apimeds Pharmaceuticals US reported revenue of $0 and net income of -$6.0M in fiscal 2025, with earnings per share of -$1.37.

When did Apimeds Pharmaceuticals US go public?

Apimeds Pharmaceuticals US stock began trading on May 9, 2025.

Drug Manufacturers - Specialty & Generic stocks

All Healthcare stocks →